JP7399730B2 - Keratinocyte PAR-2 expression inhibitor and melanocyte dendrite formation inhibitor - Google Patents
Keratinocyte PAR-2 expression inhibitor and melanocyte dendrite formation inhibitor Download PDFInfo
- Publication number
- JP7399730B2 JP7399730B2 JP2020015619A JP2020015619A JP7399730B2 JP 7399730 B2 JP7399730 B2 JP 7399730B2 JP 2020015619 A JP2020015619 A JP 2020015619A JP 2020015619 A JP2020015619 A JP 2020015619A JP 7399730 B2 JP7399730 B2 JP 7399730B2
- Authority
- JP
- Japan
- Prior art keywords
- niihime
- ripe
- extract
- pericarp
- melanin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002752 melanocyte Anatomy 0.000 title claims description 25
- 210000001787 dendrite Anatomy 0.000 title claims description 15
- 230000015572 biosynthetic process Effects 0.000 title claims description 10
- 239000003112 inhibitor Substances 0.000 title claims 3
- 210000002510 keratinocyte Anatomy 0.000 title description 21
- 230000014509 gene expression Effects 0.000 title description 13
- NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 title description 9
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 title description 9
- 101710121435 Proteinase-activated receptor 2 Proteins 0.000 title description 9
- 239000000284 extract Substances 0.000 claims description 55
- 230000019612 pigmentation Effects 0.000 claims description 11
- 235000013399 edible fruits Nutrition 0.000 claims description 10
- 230000002087 whitening effect Effects 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 50
- 230000000694 effects Effects 0.000 description 33
- 102000003425 Tyrosinase Human genes 0.000 description 27
- 108060008724 Tyrosinase Proteins 0.000 description 27
- 230000002401 inhibitory effect Effects 0.000 description 17
- 239000000203 mixture Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 10
- 208000012641 Pigmentation disease Diseases 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 241000555678 Citrus unshiu Species 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 4
- -1 Polyoxyethylene Polymers 0.000 description 4
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 4
- 235000020971 citrus fruits Nutrition 0.000 description 4
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 4
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 4
- 229940025878 hesperidin Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101100406879 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) par-2 gene Proteins 0.000 description 3
- 206010042496 Sunburn Diseases 0.000 description 3
- 206010047642 Vitiligo Diseases 0.000 description 3
- 229940008099 dimethicone Drugs 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 2
- 244000020518 Carthamus tinctorius Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000005070 ripening Effects 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- WAYINTBTZWQNSN-UHFFFAOYSA-N 11-methyldodecyl 3,5,5-trimethylhexanoate Chemical compound CC(C)CCCCCCCCCCOC(=O)CC(C)CC(C)(C)C WAYINTBTZWQNSN-UHFFFAOYSA-N 0.000 description 1
- OWEFQTXQEHYDEJ-UHFFFAOYSA-N 2,3-dihydroxypropanal diphosphono hydrogen phosphate Chemical compound OCC(O)C=O.OP(O)(=O)OP(O)(=O)OP(O)(O)=O OWEFQTXQEHYDEJ-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241001140724 Citrus tachibana Species 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N Glycyrrhetinic acid Natural products C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 108010070503 PAR-2 Receptor Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 238000010806 PrimeScriptTM RT Reagent kit Methods 0.000 description 1
- 102000018402 Protease-activated receptor 2 Human genes 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229940085262 cetyl dimethicone Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229940091554 lauryl peg-9 polydimethylsiloxyethyl dimethicone Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940031722 methyl gluceth-20 Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940088608 peg-9 polydimethylsiloxyethyl dimethicone Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明は、メラノサイトのデンドライトの形成を抑制し、さらにケラチノサイトのプロテアーゼ活性化受容体2 (protease activated receptor-2、以下PAR-2)の発現を抑制することでメラニンの取り込みを抑制することによる、皮膚における色素沈着を予防・改善する発明に関する。 The present invention suppresses melanin uptake by suppressing the formation of dendrites in melanocytes and further suppressing the expression of protease activated receptor-2 (hereinafter referred to as PAR-2) in keratinocytes. The present invention relates to an invention that prevents and improves pigmentation in the skin.
顔や手などの皮膚では他の部位に比べ紫外線に暴露される機会が多く、その結果、紫外線による一過性の色素沈着である日焼けや、老人性色素斑など年齢と共に生じる局部的な色素沈着であるシミが生じやすい。これらの色素沈着部位における病理像では表皮全域にわたる過剰なメラニンの沈着が認められ、これはメラノサイトにおけるメラニンの生成から始まる、デンドライト先端へのメラニン輸送、細胞外への放出と、ケラチノサイトに取り込まれるメラニンが最終的には垢となって肌の中から排出される過程のバランスが崩れていることが原因だと考えられる。 The skin on the face and hands has more opportunities to be exposed to ultraviolet rays than other parts of the body, resulting in sunburn, which is temporary pigmentation caused by ultraviolet rays, and local pigmentation that occurs with age, such as senile pigmentation spots. stains are likely to occur. Pathological images of these pigmented areas show excessive melanin deposition throughout the epidermis, which begins with the production of melanin in melanocytes, transport of melanin to the tips of dendrites, release to the outside of the cells, and melanin taken up by keratinocytes. This is thought to be caused by an imbalance in the process by which the skin ultimately becomes dirt and is excreted from the skin.
メラノサイトにおけるメラニン生成を抑制する方法として、メラニン産生の鍵酵素であるチロシナーゼの活性を阻害するという方法が主流であり、コウジ酸、アルブチン等の、様々な美白有効成分が開発されてきた。一方、チロシナーゼ活性阻害成分には基質であるチロシンに代わりチロシナーゼと結合することで、その活性を抑制するという作用機序を持つものが存在するが、同作用を持つロドデノールはその代謝物がメラノサイトにおける細胞障害を誘導し、尋常性白斑を引き起こすことが知られている(非特許文献1)。そのため、チロシナーゼ活性阻害作用を持つ成分は当該障害を有する可能性があり、チロシナーゼ活性阻害は高いメラニン生成抑制効果が期待できる反面、安全性に対する懸念が残る。 The mainstream method for suppressing melanin production in melanocytes is to inhibit the activity of tyrosinase, which is the key enzyme for melanin production, and various whitening active ingredients such as kojic acid and arbutin have been developed. On the other hand, some tyrosinase activity-inhibiting components have a mechanism of action that inhibits tyrosinase activity by binding to tyrosinase instead of the substrate tyrosine. It is known to induce cell damage and cause vitiligo vulgaris (Non-Patent Document 1). Therefore, ingredients that have a tyrosinase activity inhibitory effect may have this disorder, and while tyrosinase activity inhibition can be expected to have a high melanin production suppressing effect, safety concerns remain.
近年ではメラニンのメラノサイトからケラチノサイトへの受け渡しに着目した成分の開発も進められている。メラニンの受け渡し過程はメラノサイトからの放出とケラチノサイトの取り込みの過程の大きく2つに分類される。ケラチノサイトに発現するPAR-2はケラチノサイトにおけるメラニンの取り込みを制御していることが知られており、特許文献1ではキク科ベニバナ属ベニバナの抽出物にメラニン取り込み阻害効果があること、その機序がPAR-2活性阻害であることを報告している(特許文献1) In recent years, efforts have been made to develop ingredients that focus on the transfer of melanin from melanocytes to keratinocytes. The delivery process of melanin can be broadly classified into two processes: release from melanocytes and uptake by keratinocytes. It is known that PAR-2 expressed in keratinocytes controls melanin uptake in keratinocytes, and Patent Document 1 describes that an extract of Safflower of the family Asteraceae, genus Safflower, has an inhibitory effect on melanin uptake, and the mechanism thereof is explained. It has been reported that it inhibits PAR-2 activity (Patent Document 1)
一方、メラノサイトでは、細胞内で生成されたメラニンはデンドライトの先端に輸送され、ケラチノサイトに受け渡される。最近では、シミ部位におけるメラノサイトのデンドライトの数は非シミ部位に比べて有意に多いことが報告されており、このことからも1つのメラノサイトあたりのデンドライト数を減少させることが、シミ改善のための重要な機序であることが推測される(非特許文献2) On the other hand, in melanocytes, melanin produced within the cells is transported to the tips of dendrites and delivered to keratinocytes. Recently, it has been reported that the number of dendrites of melanocytes in blemished areas is significantly higher than in non-spotted areas, and this also suggests that reducing the number of dendrites per melanocyte is an effective way to improve blemishes. It is assumed that this is an important mechanism (Non-patent Document 2)
そのため、メラノサイトからのメラニンの輸送と放出を抑制するデンドライト形成抑制効果および、ケラチノサイトにおけるメラニンの取り込みを抑制する効果を併せて持つ成分が、表皮内部の過剰なメラニンの沈着に対して優れた予防効果を発揮すると考えられ、またこれらのメラニンの放出や取り込みの抑制下でメラニンが垢となって排出されることで、結果として色素沈着の改善につながると考えられる。しかしながら、そのような成分の報告例はほとんどない。 Therefore, ingredients that have the effect of suppressing dendrite formation, which suppresses the transport and release of melanin from melanocytes, and the effect of suppressing melanin uptake by keratinocytes, have an excellent preventive effect against excessive melanin deposition inside the epidermis. Furthermore, by suppressing the release and uptake of melanin, melanin is excreted as plaque, which is thought to lead to improvement of pigmentation. However, there are few reports of such components.
新姫は、熊野市新鹿町で偶然発見された新しい柑橘類で、日本古来の野性種ではなく、橘と温州みかんが自然交配した交雑品種であると言われている(非特許文献3)。起源である、温州みかん果皮抽出物に関しては美白効果が知られており、その作用機序の1つとして高いチロシナーゼ活性阻害作用が報告されている(特許文献2)。このことから、新姫果皮抽出物も高いチロシナーゼ活性阻害作用を有することが推測される。 Niihime is a new citrus fruit that was accidentally discovered in Atashika-cho, Kumano City, and is said to be not an ancient Japanese wild species, but a hybrid variety that is the natural hybridization of tachibana and Unshu mandarin (Non-patent Document 3). The origin, Satsuma mandarin peel extract, is known to have a whitening effect, and one of its mechanisms of action is reported to have a high tyrosinase activity inhibition effect (Patent Document 2). From this, it is inferred that Nihime pericarp extract also has a high tyrosinase activity inhibiting effect.
一方、特許文献3では、柑橘類に多く含まれるフラボノイドであるヘスペリジンがチロシナーゼ活性阻害効果を有していること、さらにヘスペリジンは未成熟の果皮に豊富に含まれていることから、未成熟果皮抽出物の美白成分としての有効性を示している。 On the other hand, Patent Document 3 discloses that hesperidin, a flavonoid that is abundantly contained in citrus fruits, has a tyrosinase activity inhibiting effect, and that hesperidin is abundantly contained in immature fruit peels. It has been shown to be effective as a whitening ingredient.
新姫についても、未成熟果皮にはヘスペリジンが多く含まれることが報告されている(非特許文献3)。このことから新姫の未成熟果皮抽出物の利用により従来から利用されている橘や温州みかん抽出物と同等の美白効果が期待できるが、前述したとおり、チロシナーゼ活性阻害効果を有する成分は、尋常性白斑を生じさせる危険性を完全に否定することができないため、安全性に懸念が残る。 It has also been reported that the immature pericarp of Niihime contains a large amount of hesperidin (Non-Patent Document 3). Therefore, the use of Niihime's immature peel extract can be expected to have the same whitening effect as the conventionally used Tachibana and Satsuma mandarin extracts, but as mentioned above, ingredients that inhibit tyrosinase activity are not common. As the risk of causing vitiligo cannot be completely ruled out, safety concerns remain.
一方、柑橘類の果実は成熟が進むにつれ、ヘスペリジン等のフラボノイド量が減少することが知られており、新姫についても同様の結果が示されている (非特許文献3)。そのため完熟した果皮抽出物を用いることで、チロシナーゼ活性阻害効果による尋常性白斑の危険性を減じる対策ができることが想定されるが、一方でチロシナーゼ活性阻害効果が失われることによって高い美白効果が期待できなくなるという問題が生じる。 On the other hand, it is known that the amount of flavonoids such as hesperidin decreases as citrus fruit matures, and similar results have been shown for Niihime (Non-Patent Document 3). Therefore, it is assumed that the use of ripe fruit peel extracts can reduce the risk of vitiligo due to the inhibitory effect on tyrosinase activity, but on the other hand, a high whitening effect cannot be expected due to the loss of the inhibitory effect on tyrosinase activity. The problem arises that it disappears.
このような状況下、発明者らは完熟した橘、温州みかん、新姫の果皮におけるチロシナーゼ活性阻害効果を測定したところ、起源と考えられる橘や温州みかんの果皮抽出物には比較的高いチロシナーゼ活性阻害効果が残存していたが、新姫の果皮抽出物のチロシナーゼ活性阻害効果は橘や温州みかん果皮抽出物に比して各段に低いことを発見した(図1)。 Under these circumstances, the inventors measured the inhibitory effect on tyrosinase activity in the peels of fully ripened Tachibana, Satsuma mandarin, and Niihime, and found that the tyrosinase activity was relatively high in the peel extract of Tachibana and Satsuma mandarin, which is thought to be the origin. Although the inhibitory effect remained, it was discovered that the inhibitory effect of Niihime peel extract on tyrosinase activity was much lower than that of Tachibana and Satsuma mandarin peel extracts (Figure 1).
前述したとおり、チロシナーゼ活性阻害効果が低い完熟した新姫果皮抽出物の美白効果は全く予想できないものであったが、発明者らの鋭意検討の結果、完熟した新姫果皮抽出物にメラノサイトのデンドライト形成抑制効果および、ケラチノサイトのPAR-2発現抑制効果を見出し、本発明の完成に至った。 As mentioned above, the whitening effect of the ripe Nihime peel extract, which has a low tyrosinase activity inhibition effect, was completely unexpected, but as a result of intensive study by the inventors, it was found that the ripe Nihime peel extract has melanocyte dendrites. The present invention was completed by discovering an inhibitory effect on cell formation and an inhibitory effect on PAR-2 expression in keratinocytes.
本発明は、メラノサイトにおけるチロシナーゼ活性を強く抑制することなく、メラノサイトにおけるメラニンの輸送、放出およびケラチノサイトにおけるメラニンの取り込みの双方を抑制する成分を見出すことを課題とするものである。 The object of the present invention is to find a component that suppresses both the transport and release of melanin in melanocytes and the uptake of melanin in keratinocytes without strongly suppressing tyrosinase activity in melanocytes.
完熟新姫果皮抽出物を用いることにより、上記問題を解決した。 The above problem was solved by using a ripe Niihime pericarp extract.
本発明によれば、完熟新姫果皮抽出物により、メラノサイトにおけるデンドライト形成を抑制することでメラニンの輸送、放出を抑制し、さらにケラチノサイトにおけるPAR-2発現を抑制することで、メラニンの取り込みを抑制することにより、メラノサイト-ケラチノサイト間のメラニンの受け渡しを阻害し、日焼けや老人性色素斑、炎症性色素斑などの色素沈着を改善することができる。また、完熟新姫果皮抽出物はチロシナーゼ活性を強く阻害しないため、皮膚に対する安全性面も優れている。 According to the present invention, ripe Niihime pericarp extract suppresses melanin transport and release by suppressing dendrite formation in melanocytes, and further suppresses melanin uptake by suppressing PAR-2 expression in keratinocytes. By doing so, it is possible to inhibit the transfer of melanin between melanocytes and keratinocytes and improve pigmentation such as sunburn, senile pigment spots, and inflammatory pigment spots. In addition, the ripe Niihime pericarp extract does not strongly inhibit tyrosinase activity, so it is safe for the skin.
本発明の完熟新姫果皮抽出物は、ミカン属(Citrus)新姫(tachibana/reticulata)の果皮から抽出することが出来る。ここでいう完熟新姫果皮とは、新姫の果皮の青い部分がなくなり全体が黄色になった状態のことを指すものである。新姫の果実は通常10月初旬から11月初旬に採果され、その際の果皮の外観は青である。その後、果実の成熟がすすみ、凡そ12月中旬以降に採果された果実の果皮は完熟状態であり、例えば、その時期から翌年の春までに採果された新姫の果皮はそのまま成熟果皮として使用できるほか、青い状態で採果し、その後、自然状態で放置するもしくはエチレンガスなどを用いて人工的に成熟を進める等の方法で得られる果皮を用いても問題ない。ここでいう抽出物の調製は特に限定されるものではなく、例えば水、種々適当な有機溶媒、及びこれらの混合溶媒のいずれかに投入し、低温下及び/又は加温下で抽出された物が使用できる。 The ripe Nihime pericarp extract of the present invention can be extracted from the pericarp of Citrus tachibana/reticulata. Here, fully ripe Niihime pericarp refers to the state in which the blue part of the Nihime pericarp has disappeared and the entire pericarp has turned yellow. Niihime fruit is usually harvested from early October to early November, and the skin of the fruit is blue in appearance. After that, the ripening of the fruit progresses, and the pericarp of fruits picked after mid-December is in a fully ripe state.For example, the pericarp of Niihime, which is picked from that period until the spring of the following year, remains as a mature pericarp. In addition to this, there is no problem in using the pericarp obtained by harvesting the fruit in its green state and then leaving it in its natural state or artificially ripening it using ethylene gas or the like. The preparation of the extract mentioned here is not particularly limited, and for example, it may be added to water, various suitable organic solvents, or mixed solvents thereof, and extracted at low temperature and/or under heating. can be used.
完熟新姫果皮抽出物の各剤の組成物全体に対する配合量は、有効量であれば特に限定されないが、乾燥質量に換算して0.0001~1質量%が好ましく、より好ましくは0.001~0.1質量%である。 The amount of each agent of the ripe Nihime pericarp extract relative to the entire composition is not particularly limited as long as it is an effective amount, but it is preferably 0.0001 to 1% by mass in terms of dry mass, more preferably 0.001% by mass. ~0.1% by mass.
抽出溶媒としては、特に限定はされないが例えば、水;メチルアルコール、エチルアルコール等の低級1価アルコール;グリセリン、プロピレングリコール、1,3-ブチレングリコール等の液状多価アルコール;アセトン、メチルエチルケトン等のケトン;酢酸エチルなどのアルキルエステル;ベンゼン、ヘキサン等の炭化水素;ジエチルエーテル等のエーテル類;ジクロルメタン、クロロホルム等のハロゲン化アルカン等の1種または2種以上を用いることができる。就中、水、エチルアルコール、1,3-ブチレングリコール(1,3 BG、以下BG)の1種または2種以上の混合溶媒が特に好適である。 Examples of extraction solvents include, but are not limited to, water; lower monohydric alcohols such as methyl alcohol and ethyl alcohol; liquid polyhydric alcohols such as glycerin, propylene glycol, and 1,3-butylene glycol; and ketones such as acetone and methyl ethyl ketone. One or more of the following can be used: alkyl esters such as ethyl acetate; hydrocarbons such as benzene and hexane; ethers such as diethyl ether; and halogenated alkanes such as dichloromethane and chloroform. Among these, one or a mixed solvent of two or more of water, ethyl alcohol, and 1,3-butylene glycol (1,3 BG, hereinafter referred to as BG) is particularly suitable.
以上のような条件で得られる完熟新姫果皮抽出物は、抽出された溶液のまま用いても良いが、さらに必要により濾過等の処理をして、濃縮、粉末化したものを適宜使い分けて用いることができる。 The ripe Niihime pericarp extract obtained under the above conditions may be used as an extracted solution, but if necessary, it may be further processed such as filtration, concentrated, and powdered before being used as appropriate. be able to.
以下、本発明における完熟新姫果皮抽出物の調製、効果試験等の実施例を示すが、ここに記載された実施例に限定されないのは言うまでもない。 Examples of the preparation and efficacy tests of the ripe Niihime pericarp extract in the present invention will be shown below, but it goes without saying that the present invention is not limited to the examples described here.
<試料の調製>
新姫完熟果実は熊野市ふるさと振興公社から提供されたものを使用した(2月に採果されたもの)。新姫完熟果実から果皮をとり、それを乾燥させたものをミルミキサーにて粉砕後、原体重量の10倍量の50% EtOHを添加し、60℃加温条件で3時間抽出した。これを完熟新姫果皮抽出物とする。なお比較例として新姫の起源と考えられている完熟橘果皮抽出物および完熟温州みかん果皮を使用した。この場合の「完熟」は、[0019]と同義である。
なお、次に実施するチロシナーゼ活性の測定試験では、上記抽出物を一度乾固させ、同量の50% BGに再溶解したものを使用した。固形分は約4 mg/mLであった。
<Sample preparation>
Niihime ripe fruit was provided by the Kumano City Furusato Promotion Corporation (picked in February). The pericarp was removed from the ripe Niihime fruit, dried, and ground in a mill mixer. 50% EtOH (10 times the original weight) was added thereto, and the mixture was extracted at 60°C for 3 hours. This is referred to as a ripe Niihime pericarp extract. As a comparative example, a ripe orange peel extract and a ripe unshu orange peel, which are considered to be the origin of Niihime, were used. "Ripe" in this case is synonymous with [0019].
In addition, in the next measurement test of tyrosinase activity, the above extract was dried and redissolved in the same amount of 50% BG. Solid content was approximately 4 mg/mL.
<チロシナーゼ活性の測定>
96 穴プレートを用いて、各種抽出物10μLとチロシナーゼ(2500 unit/mL、マッシュルーム由来、sigma社製)10μLを混和後、37℃で10分間インキュベートした。その後、McIlvaine’s buffer 75μL, L-チロシン75μL、蒸留水75μLの順に加え、37℃で20分間反応させた。なお、反応終了後、プレートリーダー(infinite F200Pro、TECAN)にて475nmの吸光度を測定した(A値)。コントロールは各抽出物の代わりとして50% BGを用いた。ブランクとして、L-チロシンの代わりに同量の蒸留水を使用した(B値)。チロシナーゼ活性阻害率を下記の式で求めた。
<Measurement of tyrosinase activity>
Using a 96-well plate, 10 μL of various extracts and 10 μL of tyrosinase (2500 units/mL, derived from mushroom, manufactured by Sigma) were mixed and incubated at 37° C. for 10 minutes. Thereafter, 75 μL of McIlvaine's buffer, 75 μL of L-tyrosine, and 75 μL of distilled water were added in this order, and the mixture was allowed to react at 37° C. for 20 minutes. After the reaction was completed, the absorbance at 475 nm was measured using a plate reader (infinite F200Pro, TECAN) (A value). For control, 50% BG was used instead of each extract. As a blank, the same amount of distilled water was used instead of L-tyrosine (B value). Tyrosinase activity inhibition rate was determined using the following formula.
図1に示したグラフより、完熟橘果皮抽出物、完熟温州みかん果皮抽出物では高いチロシナーゼ活性阻害効果を有しているが、完熟新姫果皮抽出物のチロシナーゼ活性阻害効果は完熟橘果皮抽出物と、完熟温州みかん果皮抽出物に比して顕著に低いことが示された。 From the graph shown in Figure 1, ripe orange peel extract and ripe unshiu orange peel extract have a high tyrosinase activity inhibitory effect, but ripe Niihime peel extract has a higher tyrosinase activity inhibitory effect than ripe orange peel extract. It was shown that the amount was significantly lower than that of the ripe Satsuma mandarin peel extract.
<メラノサイトのデンドライト形成抑制確認試験>
メラノサイトはサーモフィッシャーサイエンティフィックより、moderate donor 由来のものを購入し、使用した。メラノサイト(passage 2)は2.0×104 cell/mLになるように成長因子を含むMedium 254 に懸濁し、6wellプレートに2mLずつ播種した。5% CO2条件下、37℃で24時間インキュベートし、培地交換および試料(新姫果皮抽出物およびコントロールとして抽出物の溶媒)の添加を行った。試料は培地中に0.5%になるように添加した。3日もしくは4日に1度、試料の添加および培地交換を行い、細胞を播種してから11日後に顕微鏡(BZ-700X、キーエンス)にて、デンドライトの様子を観察し、写真撮影した。
<Melanocyte dendrite formation suppression test>
Melanocytes derived from moderate donors were purchased from Thermo Fisher Scientific and used. Melanocytes (passage 2) were suspended in Medium 254 containing growth factors to a concentration of 2.0 x 10 4 cells/mL, and 2 mL each was seeded in a 6-well plate. The cells were incubated at 37° C. under 5% CO 2 for 24 hours, followed by medium exchange and addition of samples (Nihime pericarp extract and the solvent of the extract as a control). The sample was added to the medium at a concentration of 0.5%. Samples were added and the medium was exchanged once every 3 or 4 days, and 11 days after the cells were seeded, the dendrites were observed using a microscope (BZ-700X, Keyence) and photographs were taken.
図2より、完熟新姫果皮抽出物で処置したメラノサイトは無処置のメラノサイトと比較して細胞あたりのデンドライトの数を明らかに抑制していることが確認できた。 From FIG. 2, it was confirmed that the number of dendrites per cell was clearly suppressed in melanocytes treated with the ripe Niihime pericarp extract compared to untreated melanocytes.
<ケラチノサイトにおけるPAR-2遺伝子発現確認試験>
ケラチノサイトはクラボウより新生児由来のものを購入し使用した。本実施例ではPAR-2発現の確認手法として遺伝子発現を指標としたが、タンパク発現を指標としても良い。ケラチノサイト(Passage 3)は5×104 cell/mLになるように成長因子を含むHumedia KG-2に懸濁し、24wellプレートに500μLずつ播種した。5% CO2条件下、37℃で24時間インキュベートし、培地交換および試料(新姫果皮抽出物およびコントロールとして抽出物の溶媒)の添加を行った。試料は培地中に0.5%になるように添加した。さらに、24時間インキュベート後、トータルRNAを抽出した。トータルRNAの抽出はJanaBioscience 核酸抽出キットを用いて、方法は添付のプロトコールに従った。PrimeScript RT Reagent kit (TAKARA)を用いて、逆転写を行うことでcDNAを合成した。得られたcDNAを鋳型として、PAR-2、GAPDH(グリセルアルデヒド3リン酸デヒドロゲナーゼ:ハウスキーピング遺伝子として使用)の発現量を以下のプライマー及び酵素を用いて、リアルタイムPCR (7500 RealTime PCR system、アプライドバイオシステムズ)にて測定した。
<PAR-2 gene expression confirmation test in keratinocytes>
Keratinocytes derived from newborn babies were purchased from Kurabo Industries and used. In this example, gene expression was used as an indicator as a method for confirming PAR-2 expression, but protein expression may also be used as an indicator. Keratinocytes (Passage 3) were suspended in Humedia KG-2 containing growth factors to a concentration of 5×10 4 cells/mL, and seeded in 500 μL portions onto a 24-well plate. The cells were incubated at 37° C. under 5% CO 2 for 24 hours, followed by medium exchange and addition of samples (Nihime pericarp extract and the solvent of the extract as a control). The sample was added to the medium at a concentration of 0.5%. Furthermore, after 24 hours of incubation, total RNA was extracted. Total RNA was extracted using the JanaBioscience Nucleic Acid Extraction Kit according to the attached protocol. cDNA was synthesized by reverse transcription using PrimeScript RT Reagent kit (TAKARA). Using the obtained cDNA as a template, the expression levels of PAR-2 and GAPDH (glyceraldehyde triphosphate dehydrogenase: used as a housekeeping gene) were measured using real-time PCR (7500 RealTime PCR system, Applied Biosystems).
プライマーは、PAR-2用センスプライマー(5’-GCTCTCCTTTGCCGAAGTGT-3’)、アンチセンスプライマー(5’-TTTGAGGTGAGGGATACTTGCA-3’)、GAPDH用センスプライマー(5’-CCACATCGCTCAGACACCAT-3’)、アンチセンスプライマー(5’-TGACCAGGCGCCCAATA-3’)を用いた。PCRの反応にはSYBR SELECT MASTER MIX (サーモフィッシャーサイエンティフィック)を使用し、遺伝子発現の解析は比較Ct法で行った。 The primers are sense primer for PAR-2 (5'-GCTCTCCTTTGCCGAAGTGT-3'), antisense primer (5'-TTTGAGGTGAGGGATACTTGCA-3'), sense primer for GAPDH (5'-CCACATCGCTCAGACACCAT-3'), antisense primer ( 5'-TGACCAGGCGCCCAATA-3') was used. SYBR SELECT MASTER MIX (Thermo Fisher Scientific) was used for the PCR reaction, and gene expression analysis was performed using the comparative Ct method.
図3より、コントロールと比較して完熟新姫果皮抽出物の処理によってケラチノサイトのPAR-2遺伝子発現量は抑制されることが確認できた(コントロールの遺伝子発現量を100とすると完熟新姫果皮抽出物は68に減少)。 From Figure 3, it was confirmed that the expression level of the PAR-2 gene in keratinocytes was suppressed by the treatment with the ripe Niihime pericarp extract compared to the control (when the gene expression level of the control was set to 100, the ripe Niihime pericarp extract items decreased to 68).
以下に本発明に係る組成物を作成した。尚、使用した新姫はいずれも完熟である。
<処方例1> 化粧水 (質量%)
新姫果皮抽出物(固形分) 0.02
ポリオキシエチレンソルビタンモノラウレート(20E.0.) 1.5
1,3-ブチレングリコール 5.0
グリセリン 3.0
防腐剤・酸化防止剤 適 量
香料 適 量
精製水 残 部
合 計 100.0
A composition according to the present invention was prepared below. Furthermore, all Niihime used were fully ripe.
<Formulation example 1> Lotion (mass%)
Niihime peel extract (solid content) 0.02
Polyoxyethylene sorbitan monolaurate (20E.0.) 1.5
1,3-butylene glycol 5.0
Glycerin 3.0
Preservatives/antioxidants Appropriate amount Fragrance Appropriate amount Purified water Remainder Total 100.0
<処方例2> 乳液 (質量%)
新姫果皮抽出物(固形分) 0.01
スクワラン 8.0
ワセリン 2.0
ミツロウ 0.5
ソルビタンセスキオレエート 0.8
ポリオキシエチレンオレイルエーテル(20E.0.) 1.2
カルボキシビニルポリマー 0.2
プロピレングリコール 0.5
水酸化カリウム 0.1
エタノール 7.0
防腐剤・酸化防止剤 適 量
香料 適 量
精製水 残 部
合 計 100.0
<Formulation example 2> Emulsion (mass%)
Niihime peel extract (solid content) 0.01
Squalane 8.0
Vaseline 2.0
Beeswax 0.5
Sorbitan sesquioleate 0.8
Polyoxyethylene oleyl ether (20E.0.) 1.2
Carboxyvinyl polymer 0.2
Propylene glycol 0.5
Potassium hydroxide 0.1
Ethanol 7.0
Preservatives/antioxidants Appropriate amount Fragrance Appropriate amount Purified water Remainder Total 100.0
<処方例3> クリーム (質量%)
新姫果皮抽出物(固形分) 0.001
ミツロウ 2.0
ステアリルアルコール 5.0
ステアリン酸 8.0
スクワラン 10.0
自己乳化型グリセリルモノステアレート 3.0
ポリオキシエチレンセチルエーテル(20E.0.) 1.0
プロピレングリコール 5.0
水酸化カリウム 0.3
防腐剤・酸化防止剤 適 量
香料 適 量
精製水 残 部
合 計 100.0
<Formulation example 3> Cream (mass%)
Niihime peel extract (solid content) 0.001
Beeswax 2.0
Stearyl alcohol 5.0
Stearic acid 8.0
Squalane 10.0
Self-emulsifying glyceryl monostearate 3.0
Polyoxyethylene cetyl ether (20E.0.) 1.0
Propylene glycol 5.0
Potassium hydroxide 0.3
Preservatives/antioxidants Appropriate amount Fragrance Appropriate amount Purified water Remainder Total 100.0
<処方例4> クリームファンデーション (質量%)
新姫果皮抽出物(固形分) 0.05
タルク 5.0
セリサイト 8.0
酸化チタン 5.0
色顔料 適 量
モノイソステアリン酸ポリグリセリル 3.0
ポリオキシエチレン硬化ヒマシ油 1.5
イソノナン酸イソトリデシル 10.0
1,3-ブチレングリコール 5.0
酸化防止剤 適 量
防腐剤 適 量
精製水 残 部
合 計 100.0
<Formulation example 4> Cream foundation (mass%)
Niihime peel extract (solid content) 0.05
Talc 5.0
Sericite 8.0
Titanium oxide 5.0
Color pigment Appropriate amount Polyglyceryl monoisostearate 3.0
Polyoxyethylene hydrogenated castor oil 1.5
Isotridecyl isononanoate 10.0
1,3-butylene glycol 5.0
Antioxidant Appropriate amount Preservative Appropriate amount Purified water Balance Total 100.0
<処方例5> 日焼け止め化粧料 (質量%)
新姫果皮抽出物(固形分) 0.0002
酸化チタン 10.0
酸化亜鉛 10.0
PEG-9ポリジメチルシロキシエチルジメチコン 1.5
ラウリルPEG-9ポリジメチルシロキシエチルジメチコン 1.5
シクロペンタシロキサン 20.0
ジメチコン 10.0
(ジメチコン/ビニルジメチコン)クロスポリマー 0.5
セチルジメチコン 0.25
グリチルレチン酸エステル 0.05
メチルグルセス-20 1.0
1,3-ブチレングリコール 10.0
塩化ナトリウム 適 量
酸化防止剤 適 量
防腐剤 適 量
精製水 残 部
合 計 100.0
<Formulation example 5> Sunscreen cosmetic (mass%)
Niihime peel extract (solid content) 0.0002
Titanium oxide 10.0
Zinc oxide 10.0
PEG-9 polydimethylsiloxyethyl dimethicone 1.5
Lauryl PEG-9 polydimethylsiloxyethyl dimethicone 1.5
Cyclopentasiloxane 20.0
Dimethicone 10.0
(Dimethicone/vinyl dimethicone) crosspolymer 0.5
Cetyl dimethicone 0.25
Glycyrrhetinic acid ester 0.05
Methylgluceth-20 1.0
1,3-butylene glycol 10.0
Sodium chloride Appropriate amount Antioxidant Appropriate amount Preservative Appropriate amount Purified water Balance Total 100.0
色素沈着に対する有用性を確認するため、完熟新姫果皮抽出物を含む処方例1、2、3を用い、30代~40代の頬部の色素沈着の目立ちを気にしている女性パネラー4名に対し、使用テストを実施した。テストは片側の顔に完熟新姫果皮抽出物を含む製剤を、もう片側の顔に完熟新姫果皮抽出物を抜き、水と置き換えた製剤(コントロール)を1カ月間、朝、晩洗顔後に使用した。テスト実施前後に、VISIA(登録商標) Evolution (Canfield Scientific))にて顔面頬部の写真を撮影し、画像解析によるシミスコアの平均値を算出した。シミスコアの変化率は、各製剤を適用したグループの使用後の平均値(B)を使用前の平均値(A)で割ることによって算出した。 In order to confirm its usefulness for pigmentation, formulation examples 1, 2, and 3 containing ripe Niihime pericarp extract were used to test four female panelists in their 30s and 40s who are concerned about the visibility of pigmentation on their cheeks. We conducted a usage test for this. In the test, a preparation containing ripe Niihime peel extract was applied to one face, and a preparation (control) in which the ripe Niihime peel extract was removed and replaced with water was applied to the other face for one month after washing the face in the morning and evening. did. Before and after the test, photographs of the facial and cheek areas were taken using VISIA (registered trademark) Evolution (Canfield Scientific), and the average value of the stain score was calculated by image analysis. The rate of change in stain score was calculated by dividing the average value after use (B) of the group to which each formulation was applied by the average value before use (A).
表1より、完熟新姫果皮抽出物を使用することによる色素沈着の改善効果が確認できた。 From Table 1, it was confirmed that the pigmentation improvement effect was achieved by using the ripe Niihime pericarp extract.
本発明によれば、完熟新姫果皮抽出物により、メラノサイトにおけるデンドライト形成を抑制することでメラニンの輸送、放出を抑制し、さらにケラチノサイトにおけるメラニンの取り込みを抑制することにより、メラノサイト-ケラチノサイト間のメラニンの受け渡しを阻害することで、表皮内のメラニン量を減少させることを可能にし、日焼けや老人性色素斑、炎症性色素斑などの色素沈着を改善することができる。また、完熟新姫果皮抽出物はチロシナーゼ活性を強く抑制しないため、チロシナーゼ活性阻害作用を持つ成分を含む従来の美白化粧料と比して皮膚に対する安全性面も優れている。
According to the present invention, ripe Niihime pericarp extract suppresses dendrite formation in melanocytes, thereby suppressing melanin transport and release, and further suppresses melanin uptake in keratinocytes, thereby promoting melanin formation between melanocytes and keratinocytes. By inhibiting the delivery of melanin, it is possible to reduce the amount of melanin in the epidermis and improve pigmentation such as sunburn, senile pigment spots, and inflammatory pigment spots. Furthermore, since the ripe Nihime pericarp extract does not strongly inhibit tyrosinase activity, it is safer for the skin than conventional whitening cosmetics that contain ingredients that inhibit tyrosinase activity.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020015619A JP7399730B2 (en) | 2020-01-31 | 2020-01-31 | Keratinocyte PAR-2 expression inhibitor and melanocyte dendrite formation inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020015619A JP7399730B2 (en) | 2020-01-31 | 2020-01-31 | Keratinocyte PAR-2 expression inhibitor and melanocyte dendrite formation inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021123534A JP2021123534A (en) | 2021-08-30 |
| JP7399730B2 true JP7399730B2 (en) | 2023-12-18 |
Family
ID=77458104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020015619A Active JP7399730B2 (en) | 2020-01-31 | 2020-01-31 | Keratinocyte PAR-2 expression inhibitor and melanocyte dendrite formation inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7399730B2 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007223965A (en) | 2006-02-24 | 2007-09-06 | National Institute Of Advanced Industrial & Technology | Epidermal keratinocyte endothelin-1 production inhibitor |
| JP2015202065A (en) | 2014-04-11 | 2015-11-16 | 株式会社 沖縄リサーチセンター | Fermentation processed product and method for producing nobiletin and tangeretin high content product |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2873921B2 (en) * | 1995-03-24 | 1999-03-24 | 農林水産省果樹試験場長 | Water-soluble antioxidant composition |
| JP3993936B2 (en) * | 1998-05-22 | 2007-10-17 | 一丸ファルコス株式会社 | Melanin production inhibitor and cosmetic composition |
| JP2002060332A (en) * | 2000-08-17 | 2002-02-26 | Nof Corp | Skin cosmetics |
| KR101802355B1 (en) * | 2016-04-25 | 2017-11-28 | 명지대학교 산학협력단 | Composition for regenerating skin tissue comprising extract of citrus preicarp |
-
2020
- 2020-01-31 JP JP2020015619A patent/JP7399730B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007223965A (en) | 2006-02-24 | 2007-09-06 | National Institute Of Advanced Industrial & Technology | Epidermal keratinocyte endothelin-1 production inhibitor |
| JP2015202065A (en) | 2014-04-11 | 2015-11-16 | 株式会社 沖縄リサーチセンター | Fermentation processed product and method for producing nobiletin and tangeretin high content product |
Non-Patent Citations (2)
| Title |
|---|
| Conc,ID 10603086,Mintel GNPD[online],2023年2月,[検索日2023.08.17],URL,https://www.portal.mintel.com |
| 市ノ木山浩道ら,香酸カンキツ'新姫'の全果実および部位別フラボノイド含有量,園学研(2012),Vol.11, No.3,p.387-391 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021123534A (en) | 2021-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9675543B2 (en) | Method of improving aging appearance of skin by modulation of WIPI-1 | |
| FR2924334A1 (en) | COSMETIC COMPOSITION COMPRISING ASCORBIC 2-GLUCOSIDE ACID AND ERGOTHIONEIN | |
| US11491102B2 (en) | Composition for skin anti-inflammation and skin moisturizing comprising artemisia extract extracted with skin cosmetic solution as a solvent | |
| JP2022137078A (en) | Alcoholic extract of aerial parts of anthyllis vulneraria, method for obtaining the same, and cosmetic or pharmaceutical composition containing the same | |
| JPH04342519A (en) | Skin cosmetic | |
| EP1401383A2 (en) | Use of at least an oil extracted from the seeds of the gourd family for preparing a composition for inhibiting 5-alpha-reductase activity | |
| JP5701480B2 (en) | Antioxidant | |
| WO2014075866A2 (en) | A skin lightening composition | |
| JP7399730B2 (en) | Keratinocyte PAR-2 expression inhibitor and melanocyte dendrite formation inhibitor | |
| FR2954702A1 (en) | AGENT STIMULATING THE EXPRESSION OF LOXL | |
| WO2019077268A1 (en) | Cosmetic composition for active prevention of the signs of ageing | |
| JP2000159631A (en) | Collagenase inhibitor | |
| JP2001097844A (en) | Anti-aging agent and cosmetic containing the same and used for preventing aging | |
| JPH10236941A (en) | Skin lotion | |
| JP2000159626A (en) | Preparation for external use for skin | |
| JP6474681B2 (en) | White hair prevention or improvement cosmetics | |
| JPH092967A (en) | Tyrosinase activity inhibitor and cosmetics containing the same | |
| JP7648359B2 (en) | Mitochondrial function improver | |
| JP7470270B2 (en) | MELANOSOMAL TRANSPORT INHIBITOR AND EXTERNAL SKIN PREPARATION CONTAINING THE TRANSPORT INHIBITOR | |
| FR2924335A1 (en) | Use of ascorbic acid 2-glucoside, as active ingredient in a cosmetic composition e.g. to mitigate effects of skin aging or delay the appearance of the effects, and to reduce or delay the formation of wrinkles and firmness of the skin | |
| FR3066118A1 (en) | EDULATED SECUMUM EXTRACT TO FIGHT THE HARMFUL EFFECTS OF ULTRAVIOLET RADIATION | |
| JPH08175964A (en) | Skin preparation for external use | |
| FR3150440A1 (en) | Composition comprising different extracts | |
| JPH0812564A (en) | Skin external preparation | |
| KR20060034124A (en) | Cosmetic composition for sebum production inhibition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220927 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230809 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230829 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231025 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231205 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231206 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7399730 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |